Why the study?
CCM provides a novel heart failure treatment, particularly for patients unresponsive to CRT within specific QRS ranges, but its mechanistic underpinnings, impact, and clinical limitations require elucidation.
Cardiac contractility modulation is a potential therapeutic option for heart failure patients unresponsive to CRT, but requires further research on hard clinical outcomes and combinatory strategies.
CCM may aid myocardial function in select HF patients; leaves open mortality/hospitalization effects and combinatory strategies.
Cardiac contractility modulation (CCM) offers a novel therapeutic avenue for heart failure patients, particularly those unresponsive to cardiac resynchronization therapy within specific QRS duration ranges. This review elucidates CCM's mechanistic underpinnings, its impact on myocardial function, and utility across patient demographics. However, CCM is limited by insufficient data on mortality and hospitalization rate reductions, as well as the need for specialized device implantation skills. While prevailing research has concentrated on left ventricular effects, a knowledge gap persists for other patient subsets. Future inquiries should address combinatory treatment strategies, extended usage and the impact of atrial fibrillation on device implantation. Such expanded studies could refine therapeutic outcomes and widen the scope of beneficiaries.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: